DK3678668T3 - ENPP1-inhibitorer og deres anvendelse til behandling af kræft - Google Patents

ENPP1-inhibitorer og deres anvendelse til behandling af kræft Download PDF

Info

Publication number
DK3678668T3
DK3678668T3 DK18779884.8T DK18779884T DK3678668T3 DK 3678668 T3 DK3678668 T3 DK 3678668T3 DK 18779884 T DK18779884 T DK 18779884T DK 3678668 T3 DK3678668 T3 DK 3678668T3
Authority
DK
Denmark
Prior art keywords
cancer
treatment
enpp1 inhibitors
enpp1
inhibitors
Prior art date
Application number
DK18779884.8T
Other languages
Danish (da)
English (en)
Inventor
Lingyin Li
Mark Smith
Kelsey Erin Shaw
Jacqueline Ann Carozza
Volker Boehnert
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of DK3678668T3 publication Critical patent/DK3678668T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C07F9/1651—Esters of thiophosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3826—Acyclic unsaturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44—Amides thereof
    • C07F9/4403—Amides thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4407—Amides of acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK18779884.8T 2017-09-08 2018-09-07 ENPP1-inhibitorer og deres anvendelse til behandling af kræft DK3678668T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762556117P 2017-09-08 2017-09-08
PCT/US2018/050018 WO2019051269A1 (en) 2017-09-08 2018-09-07 ENPP1 INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER

Publications (1)

Publication Number Publication Date
DK3678668T3 true DK3678668T3 (da) 2024-04-08

Family

ID=63714052

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18779884.8T DK3678668T3 (da) 2017-09-08 2018-09-07 ENPP1-inhibitorer og deres anvendelse til behandling af kræft

Country Status (18)

Country Link
US (3) US11701371B2 (enExample)
EP (2) EP4327882A3 (enExample)
JP (2) JP7292740B2 (enExample)
KR (2) KR102715420B1 (enExample)
CN (2) CN117883449A (enExample)
AU (2) AU2018330188C1 (enExample)
BR (1) BR112020004559A2 (enExample)
CA (1) CA3074268A1 (enExample)
DK (1) DK3678668T3 (enExample)
EA (1) EA202090595A1 (enExample)
ES (1) ES2975183T3 (enExample)
HU (1) HUE066413T2 (enExample)
IL (3) IL311010A (enExample)
MA (1) MA50082A (enExample)
MX (2) MX2020002646A (enExample)
PL (1) PL3678668T3 (enExample)
SG (1) SG11202001728YA (enExample)
WO (1) WO2019051269A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020140001A1 (en) * 2018-12-28 2020-07-02 Riboscience Llc Quinazoline derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
ES2960987T3 (es) 2019-04-12 2024-03-07 Riboscience Llc Derivados de heteroarilo bicíclicos como inhibidores de la ectonucleótido pirofosfatasa fosfodiesterasa 1
CN114728971B (zh) 2019-09-16 2025-05-13 阿托恩波罗斯生命科学私人有限公司 作为enpp1蛋白的抑制剂的2-氨基-s6-取代的硫嘌呤化合物
KR20220068243A (ko) * 2019-09-23 2022-05-25 난징 젱시앙 파마슈티칼스 컴퍼니 리미티드 포스포디에스테라제 억제제 및 용도
CN115362145B (zh) * 2020-02-04 2025-05-02 斯汀格瑞治疗股份有限公司 外核苷酸焦磷酸酶/磷酸二酯酶1(enpp1)抑制剂及其使用方法
AU2021224588B2 (en) 2020-02-18 2024-07-18 Gilead Sciences, Inc. Antiviral compounds
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
WO2021203772A1 (en) * 2020-04-09 2021-10-14 Betta Pharmaceuticals Co., Ltd Ectonucleotide pyrophosphatase-phosphodiesterase 1 inhibitors,compositions and uses thereof
WO2021225969A1 (en) * 2020-05-04 2021-11-11 Volastra Therapeutics, Inc. Imino sulfanone inhibitors of enpp1
KR102682428B1 (ko) 2020-05-08 2024-07-05 주식회사 티씨노바이오사이언스 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 프탈라진 유도체 및 이들의 용도
EP4148046A4 (en) 2020-05-08 2024-07-24 Txinno Bioscience Inc. NEW PHTHALAZINE DERIVATIVE WITH ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE INHIBITING ACTIVITY AND USE THEREOF
WO2021257614A1 (en) * 2020-06-16 2021-12-23 Volastra Therapeutics, Inc. Heterocyclic inhibitors of enpp1
CN116234802A (zh) 2020-09-03 2023-06-06 免疫传感器治疗股份有限公司 喹啉cgas拮抗剂化合物
JP2023549738A (ja) * 2020-10-30 2023-11-29 １シーバイオ， インコーポレイテッド エクトヌクレオチドピロホスファターゼ－ホスホジエステラーゼ－１（ｅｎｐｐ１）阻害物質及びそれらの使用
US20250099493A1 (en) * 2020-12-09 2025-03-27 Stingray Therapeutics, Inc. Phosphonates as inhibitors of enpp1 and cdnp
CN116600813A (zh) * 2020-12-09 2023-08-15 斯汀格瑞治疗股份有限公司 作为enpp1和cdnp抑制剂的膦酸盐
KR102720206B1 (ko) 2020-12-29 2024-10-21 주식회사 티씨노바이오사이언스 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 나프티리딘온 유도체 및 이들의 용도
WO2022146022A1 (ko) 2020-12-29 2022-07-07 주식회사 티씨노바이오사이언스 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 나프티리딘온 유도체 및 이들의 용도
KR102686866B1 (ko) 2021-01-29 2024-07-19 주식회사 티씨노바이오사이언스 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 벤조트리아졸 유도체 및 이들의 용도
CA3204409A1 (en) 2021-01-29 2022-08-04 Chan Sun Park Novel benzotriazole derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase, and use thereof
US20240209005A1 (en) * 2021-03-16 2024-06-27 Riboscience Llc Bicyclic heteroaryl boronate derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
KR20230170745A (ko) 2021-04-16 2023-12-19 길리애드 사이언시즈, 인코포레이티드 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법
CN115536696B (zh) * 2021-06-29 2023-07-14 上海齐鲁制药研究中心有限公司 Enpp1抑制剂
US12116380B2 (en) 2021-08-18 2024-10-15 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
WO2023035001A1 (en) * 2021-09-03 2023-03-09 Angarus Therapeutics, Inc. Enpp1 inhibitors and immune cells expressing chimeric antigen receptors
WO2023077083A1 (en) * 2021-10-29 2023-05-04 Angarus Therapeutics, Inc. Enpp1 inhibitors as inhibitors of metastasis
AU2023228915A1 (en) 2022-03-02 2024-09-19 Immunesensor Therapeutics, Inc. QUINOLINE cGAS ANTAGONIST COMPOUNDS
WO2023197987A1 (zh) * 2022-04-11 2023-10-19 上海齐鲁制药研究中心有限公司 Enpp1抑制剂
US20230346771A1 (en) 2022-04-29 2023-11-02 Petragen, Inc. Inhibitors of enpp1 and modulation of bone growth
CN114767863B (zh) * 2022-04-29 2024-01-30 西北工业大学 一种enpp2基因或蛋白在调控结直肠癌细胞中的应用
WO2024028727A1 (en) * 2022-08-01 2024-02-08 Sravathi Ai Technology Private Limited Novel ectonucleotide pyrophosphatase / phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
CN120981233A (zh) * 2023-04-11 2025-11-18 香港科技大学 由新型enpp1抑制剂使轴突再生
WO2024216211A2 (en) * 2023-04-14 2024-10-17 The Board Of Trustees Of The Leland Stanford Junior University Methods of inhibiting tumor progression and metastasis by inhibition of enpp1
WO2025207514A1 (en) * 2024-03-25 2025-10-02 Riboscience Llc Bicyclic heteroaryl sulfanediimine derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA228044A (en) 1923-01-16 Thomas Noble Boughton Die for forming bolts
CA190896A (en) 1919-02-24 1919-06-17 Josephat C. Bergeron Advertising device
DE3319795A1 (de) 1983-06-01 1984-12-06 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von phosphonsaeureestern
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
KR100408909B1 (ko) 1995-04-21 2004-04-29 데이꼬꾸 조끼 세이야꾸 가부시키가이샤 신규펩티드유도체
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US6960580B2 (en) 2001-03-08 2005-11-01 Millennium Pharmaceuticals, Inc. Nitrogenous heterocyclic substituted quinoline compounds
US20040101840A1 (en) * 2001-04-27 2004-05-27 Chung Leland W.K. Identification, cloning and characterization of a novel pc-1 gene differentially expressed in prostate cells and tissues
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
BRPI0317717B8 (pt) 2002-12-24 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, e uso de um composto
US20070004763A1 (en) 2005-06-10 2007-01-04 Nand Baindur Aminoquinoline and aminoquinazoline kinase modulators
US10543207B2 (en) 2008-12-31 2020-01-28 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2012041872A1 (en) * 2010-09-29 2012-04-05 Intervet International B.V. N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases
EP2794630A4 (en) 2011-12-22 2015-04-01 Alios Biopharma Inc SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE
JP2016518140A (ja) 2013-05-03 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｉ型インターフェロンの環状ジヌクレオチド誘導法
CU24377B1 (es) 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
US9862703B2 (en) * 2014-09-22 2018-01-09 National Health Research Institutes Heterocyclic compounds and use thereof
US10011600B2 (en) * 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
CN105153153A (zh) 2015-08-31 2015-12-16 吉林奥来德光电材料股份有限公司 一种新的芳香族胺类化合物及其制备与应用
TWI659949B (zh) 2016-05-16 2019-05-21 臺北醫學大學 組蛋白去乙醯酶6抑制劑及其用途
BR112019012630A2 (pt) 2016-12-22 2019-11-19 Mavupharma Inc composições e métodos para melhorar ou aumentar a produção de ifn tipo i
WO2018127928A1 (en) 2017-01-09 2018-07-12 The Australian National University Synergists for improved pesticides
US10518257B2 (en) 2017-05-04 2019-12-31 Exxonmobil Research And Engineering Company Metal organic frameworks, their synthesis and use
WO2018229139A1 (en) 2017-06-14 2018-12-20 Fundación Para La Investigación Médica Aplicada Novel compounds for use in cancer
SG11202001664VA (en) 2017-08-31 2020-03-30 Abbvie Inc Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
SG11202108288YA (en) 2019-02-01 2021-08-30 Univ Leland Stanford Junior Enpp1 inhibitors and methods of modulating immune response
CN114437128B (zh) * 2022-01-28 2023-12-19 中国科学院长春应用化学研究所 一种胆碱磷酸修饰的紫杉醇药物及其制备方法和应用

Also Published As

Publication number Publication date
AU2018330188A1 (en) 2020-04-23
AU2024200148A1 (en) 2024-01-25
RU2020112299A (ru) 2021-10-08
KR102715420B1 (ko) 2024-10-10
IL302338B2 (en) 2024-10-01
IL272948B1 (en) 2023-05-01
CN111372587A (zh) 2020-07-03
KR20200066292A (ko) 2020-06-09
EP4327882A2 (en) 2024-02-28
MA50082A (fr) 2020-07-15
MX2023007193A (es) 2023-07-03
US20230103498A1 (en) 2023-04-06
EP4327882A3 (en) 2024-05-15
CA3074268A1 (en) 2019-03-14
IL311010A (en) 2024-04-01
WO2019051269A1 (en) 2019-03-14
IL302338B1 (en) 2024-06-01
PL3678668T3 (pl) 2024-06-03
JP2023101715A (ja) 2023-07-21
CN111372587B (zh) 2024-01-09
MX2020002646A (es) 2020-09-25
SG11202001728YA (en) 2020-03-30
KR20240151869A (ko) 2024-10-18
AU2018330188C1 (en) 2024-02-29
IL302338A (en) 2023-06-01
JP2020533288A (ja) 2020-11-19
US20210369747A1 (en) 2021-12-02
IL272948B2 (en) 2023-09-01
JP7292740B2 (ja) 2023-06-19
AU2018330188B2 (en) 2023-10-19
EP3678668B1 (en) 2024-01-10
CN117883449A (zh) 2024-04-16
BR112020004559A2 (pt) 2020-09-24
HUE066413T2 (hu) 2024-08-28
RU2020112299A3 (enExample) 2022-03-14
US11701371B2 (en) 2023-07-18
ES2975183T3 (es) 2024-07-03
EA202090595A1 (ru) 2020-06-29
US20230277570A1 (en) 2023-09-07
IL272948A (en) 2020-04-30
JP7607969B2 (ja) 2025-01-06
EP3678668A1 (en) 2020-07-15
US11707471B2 (en) 2023-07-25

Similar Documents

Publication Publication Date Title
DK3678668T3 (da) ENPP1-inhibitorer og deres anvendelse til behandling af kræft
DK3558997T3 (da) Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer
DK3285809T3 (da) Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner.
DK3612517T3 (da) Bicykliske forbindelser og deres anvendelse ved behandling af cancer
DK3307727T3 (da) Heterocykliske inhibitorer af erk1 og erk2 og deres anvendelse i behandlingen af kræft
DK3368069T3 (da) Anvendelse af myostatininhibitorer og kombinationsterapier
DK3658557T3 (da) Tyk2-inhibitorer og anvendelser deraf
DK3452485T3 (da) Arginasehæmmere og deres terapeutiske anvendelser
DK3256218T3 (da) Kdm1a-hæmmer og anvendelse deraf i terapi
DK3672954T3 (da) Forbindelser og salte deraf og deres anvendelse til behandling af sygdomme
DK3134125T3 (da) Antistof-lægemiddel-konjugat og anvendelse deraf til behandling af cancer
DK3331900T3 (da) Peptider og kombination af peptider til anvendelse ved immunterapi mod prostatacancer og andre cancere
DK3325488T3 (da) Chiral diaryl-makrocyklus og anvendelse deraf til behandling af cancer
DK3445388T3 (da) Materialer og fremgangsmåder til behandling af hæmoglobinopatier
DK4234581T3 (da) Terapeutiske antistoffer og deres anvendelse
DK3322425T3 (da) Genmodificerede anti-tredjeparts-centralhukommelse-t-celler og brug af samme i immunterapi
DK3860990T3 (da) Inhibitorer for YAP/TAZ-TEAD interaktion og disses anvendelse ved behandlingen af cancer
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3303339T3 (da) Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme
DK3621694T3 (da) Lrrc33-inhibitorer og anvendelse heraf
DK3474883T3 (da) Komplementinhibitorer og anvendelser deraf
DK3790879T3 (da) Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft
DK3273995T3 (da) Kombineret anvendelse af alginatoligomerer og cftr-modulatoren lumacaftor i behandlingen af tilstande associeret med cftr-dysfunktion
DK3532459T3 (da) Lsd1-hæmmere og medicinske anvendelser deraf
DK3293201T3 (da) Kombinering af adenovirus og checkpoint-inhibitorer til behandling af cancer